# Retinocytoma: understanding pathogenesis, diagnosis, and treatment approaches

## TL;DR

This paper reviews retinocytoma, a rare benign eye tumor, focusing on its causes, diagnosis, and treatment, and its connection to retinoblastoma.

## Contribution

The paper provides an updated review of retinocytoma's pathogenesis, diagnosis, and management strategies.

## Key findings

- Retinocytoma is linked to RB1 gene mutations and may precede retinoblastoma.
- Patients with retinocytoma generally have a good prognosis with regular monitoring.
- Treatment typically involves observation unless malignant transformation is suspected.

## Abstract

Retinocytoma, or retinoma, is a rare benign intraocular tumor primarily affecting the retina. It is often considered a precursor or a differentiated form of retinoblastoma, a malignant retinal tumor predominantly seen in children. Despite its non-aggressive nature and excellent prognosis, retinocytoma remains a significant area of interest due to its implications for genetic counseling, early detection, and management of ocular tumors. The pathogenesis of retinocytoma is closely linked to mutations in the RB1 gene, which plays a vital role in regulating the cell cycle. The detection of RB1 mutations in peripheral blood indicates germline disease, substantially elevating the risk of bilateral retinoblastoma development. Despite its benign nature, retinocytoma necessitates vigilant monitoring due to its potential to transform into retinoblastoma. Current treatment strategies primarily focus on observation and regular follow-up. However, more aggressive treatments are considered if malignant transformation is suspected. The prognosis is generally favorable, with most patients maintaining good visual acuity and a low risk of progression to retinoblastoma. We aim to present an up-to-date review on epidemiology, clinical features, pathogenesis, macroscopic and histopathological features, diagnostic criteria, prognosis, and management strategies.